Drugs Health Pharma

Governments, philanthropic partners pledge $170 million to WHO

HQ Team May 21, 2025: Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total.

Read More
Drugs Health Pharma

Novo Nordisk, Septerna in $2.2b deal to develop oral molecules

HQ Team May 14, 2025: Novo Nordisk and Septerna, Inc., have inked a $2.2 billion global collaboration and licensing pact to develop oral.

Read More
Drugs Medical Pharma

Novo Nordisk to invest $1.05b in Monte Claros facility in Brazil

HQ Team April 10, 2025: Novo Nordisk will invest 6.4 billion reais ($1.05 billion) in Brazil’s Monte Claros to expand its production of.

Read More
Drugs Medical Pharma

Novo Nordisk in $2b deal with Chinese firm for ‘triple-G’ obesity drug

HQ Team February 25, 2025: Novo Nordisk has inked a $2 billion licensing pact with United Laboratories International for the development, manufacturing and.

Read More
Drugs Medical Pharma

Novo Nordisk to pay US-based Gensaic $354 million upfront in licensing deal

HQ Team March 5, 2025: Novo Nordisk will pay Gensaic, Inc., a biotechnology company, an upfront payment of $354 million for the latter’s.

Read More
Drugs Health Medical

Novo’ Nordisk’s drug to cut kidney disease advance in diabetics gets nod

Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular.

Read More
Drugs Health Medical

Novo Nordisk, Valo expand pact to include obesity, diabetic drugs

Novo Nordisk A/S, a Danish pharmaceutical company, has expanded its agreement with US-based Valo Health Inc., almost to double the number of drugs.

Read More
Uncategorized

Novo Nordisk says its drug CargiSema cuts body weight by 22.7% in adults

Danish pharmaceutical company Novo Nordisk’s combination drug achieved a 22.7% weight-loss reduction compared to a dummy drug during end-stage trials, according to a.

Read More
Drugs Health Pharma

Novo Nordisk’s weight loss drug reduces liver scarring in end-stage trial

Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without.

Read More
Drugs Health Pharma

Novo’s type 2 oral diabetic drug cuts heart diseases by 14% in a trial

Danish pharmaceutical company, Novo Nordisk’s oral semaglutide drug to treat type 2 diabetes helped reduce heart diseases by 14% compared to a dummy.

Read More